Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) Insider Sells $877,500.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) insider John Tilton sold 30,000 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.25, for a total value of $877,500.00. Following the completion of the transaction, the insider now owns 30,000 shares in the company, valued at $877,500. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) opened at $25.39 on Tuesday. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $17.00 and a 1-year high of $39.51.

ILLEGAL ACTIVITY WARNING: This news story was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.truebluetribune.com/2017/11/14/insider-selling-biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-sells-877500-00-in-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Deschutes Portfolio Strategy LLC bought a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter valued at about $374,000. Strs Ohio bought a new position in Biohaven Pharmaceutical Holding Co during the third quarter worth about $680,000. Emerald Mutual Fund Advisers Trust bought a new position in Biohaven Pharmaceutical Holding Co during the third quarter worth about $7,483,000. Emerald Advisers Inc. PA bought a new position in Biohaven Pharmaceutical Holding Co during the third quarter worth about $9,096,000. Finally, Alps Advisors Inc. bought a new position in Biohaven Pharmaceutical Holding Co during the third quarter worth about $1,316,000.

A number of research analysts have recently weighed in on BHVN shares. Morgan Stanley increased their price target on Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. BidaskClub downgraded Biohaven Pharmaceutical Holding Co from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $40.80.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply